Incyte Corporation

H. Lee Moffitt Cancer Center and Research Institute, Inc.

Other

Holly Koblish

Gary Reuther

Giorgio Trinchieri

Jonathan Rios-Doria

Rodrigo Hess

William M F Lee

The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors

The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.

Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent

The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.

Low dose combination therapy for treatment of myeloproliferative neoplasms

Methods for enhancing the therapeutic and adjuvant use of IL-12 by reducing unwanted transient immunosuppression caused by IL-12 or by high doses thereof involve co-administering IL-12 with an effective amount of an agent that inhibits or neutralizes nitric oxide (NO) in vivo. Enhanced vaccine therapy involves co-administering the IL-12 adjuvant, a selected vaccine antigen and the NO inhibiting/neutralizing agent. Additionally, the toxicity of IL-12 treatment may be reduced by co-administering IL-12 with an effective amount of the NO inhibiting or neutralizing agent. A therapeutic composition characterized by reduced toxicity in mammals contains IL-12, preferably a low dose thereof, and an NO inhibiting or neutralizing agent in a pharmaceutically acceptable carrier. A vaccine composition contains an effective adjuvanting amount of IL-12, an effective amount of an NO inhibiting or neutralizing agent, and an effective protective amount of a vaccine antigen in a pharmaceutically acceptable carrier.

Growing community of inventors

Exton, PA, United States of America

Holly Koblish